hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06375148, orgStudyIdInfo id: Yan2024-0052, briefTitle: A Questionnaire Survey on Cognition of Enteral Nutrition Implementation in Patients Requiring Mechanical Ventilation in Prone Position, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2024-05-30, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Second Affiliated Hospital, School of Medicine, Zhejiang University, class: OTHER, descriptionModule briefSummary: Prone ventilation is an important treatment for respiratory failure with intractable hypoxia, and the Corona Virus Disease 2019(COVID-19 ) outbreak has further elevated the status of prone ventilation. Early enteral nutrition (EN) is also recognised as an important measure to improve the prognosis of critically ill patients. However, the administration of enteral nutrition during prone position is still quite controversial. In this paper, we analysed the tolerance and safety of enteral nutrition in the prone position by reviewing studies before and after the COVID-19 outbreak. Key strategies to improve the tolerability of enteral nutrition in the prone position are also summarised and discussed., conditionsModule conditions: Enteral Nutrition, conditions: Prone Position, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Enteral nutrition, outcomesModule primaryOutcomes measure: A questionnaire survey on cognition of enteral nutrition implementation in patients requiring mechanical ventilation in prone position, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Second Affiliated Hospital of Zhejiang University School of Medicine, city: Zhenjiang, country: China, geoPoint lat: 32.21086, lon: 119.45508, hasResults: False
protocolSection identificationModule nctId: NCT06375122, orgStudyIdInfo id: 10001951, secondaryIdInfos id: 001951-C, briefTitle: Natural History Study of Kaposi Sarcoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2034-12-31, completionDateStruct date: 2036-12-31, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: National Cancer Institute (NCI), class: NIH, descriptionModule briefSummary: Background:Kaposi sarcoma (KS) is a type of tumor caused by the Kaposi sarcoma herpesvirus. KS usually affects the skin, but lesions can also appear in the lymph nodes, lungs and digestive tract. KS is most common in people with compromised immunity, but it also appears in otherwise healthy people. Researchers want to understand more about how KS develops, why it may recur, and how it affects the immune system and organs.Objective:To learn more about the natural history of KS.Eligibility:People aged 18 years and older with KS.Design:Participants will be screened. They will have a physical exam with blood tests. They will have an imaging scan. They may need a new biopsy: Tissue samples may be cut from their tumor. Their ability to perform normal activities will be assessed.Participants will visit the clinic to have their KS evaluated. In addition to the imaging scans and other tests performed during screening, procedures may include:Eye exam.Ultrasound exam of the heart (electrocardiogram).Collection of saliva and urine samples.Biopsies of the skin or lymph nodes.Swabs of the anus and cervix.Photographs of skin lesions.Removal of fluid samples from the space around the lungs, intestine, or heart.The evaluation visit will be repeated 5 more times over 18 months and then yearly for up to 10 years.Participants will follow their standard treatment for KS during the study., conditionsModule conditions: Kaposi Sarcoma, conditions: HIV, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: To characterize the natural history of KS, including presentation, manifestation, and proportion of participants with KS with remission and recurrence by epidemiologic subtype, secondaryOutcomes measure: To evaluate differences in rates of KS recurrence by HIV status and CD4 T cell count, secondaryOutcomes measure: To evaluate the emergence of KSHV-associated inflammatory syndromes in the natural history of KS, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 120 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Institutes of Health Clinical Center, city: Bethesda, state: Maryland, zip: 20892, country: United States, contacts name: National Cancer Institute Referral Office, role: CONTACT, phone: 888-624-1937, email: ncimo_referrals@mail.nih.gov, geoPoint lat: 38.98067, lon: -77.10026, hasResults: False
protocolSection identificationModule nctId: NCT06375109, orgStudyIdInfo id: BJXK-2023-KY-53, secondaryIdInfos id: NeoSCLC-001, type: OTHER, domain: Beijing Chest Hospital, Capital Medical University, briefTitle: PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC, acronym: NeoSCLC-001, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-16, primaryCompletionDateStruct date: 2027-04-15, completionDateStruct date: 2029-04-15, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Beijing Chest Hospital, Capital Medical University, class: OTHER, descriptionModule briefSummary: This is an open-label, non-randomized, controlled, single-center, phase II study to compare the efficacy and safety of neoadjuvant PD-L1/PD-1 inhibitor + chemotherapy (carboplatin/cisplatin + etoposide) with chemotherapy (carboplatin/cisplatin + etoposide) alone followed by radical surgery and adjuvant treatment as perioperative therapy in patients with limited-stage SCLC., conditionsModule conditions: Limited-stage Small-cell Lung Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Tislelizumab, interventions name: Carboplatin injection, interventions name: Cisplatin injection, interventions name: Etoposide injection, outcomesModule primaryOutcomes measure: Pathologic Complete Response (pCR) Rate, secondaryOutcomes measure: Major Pathologic Response (MPR) Rate, secondaryOutcomes measure: Event-Free Survival (EFS), secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Safety: frequency of severe adverse events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06375096, orgStudyIdInfo id: Graves' disease, briefTitle: Bone Mineral Density in Children With Graves' Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-25, primaryCompletionDateStruct date: 2025-06-25, completionDateStruct date: 2025-06-25, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: to evaluate bone mineral density in children with graves' disease, conditionsModule conditions: Bone Density, Low, conditions: Bone Mineral Density in Children With Graves' Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: evaluate bone mineral density, outcomesModule primaryOutcomes measure: bone mineral density, eligibilityModule sex: ALL, minimumAge: 2 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06375083, orgStudyIdInfo id: 23-1231, briefTitle: Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: VA Eastern Colorado Health Care System, class: FED, descriptionModule briefSummary: This study plans to learn more about the use of one of two self-guided online cognitive behavioral therapy courses. One is focused on symptoms of depression and one is focused on history of suicidal thoughts and behaviors., conditionsModule conditions: Suicide, conditions: Depression, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Cognitive Behavioral Therapy for Suicide Prevention (cCBT-SP) and Cognitive Behavioral Therapy for Depression (cCBT-D), primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 472, type: ESTIMATED, armsInterventionsModule interventions name: Cognitive Behavioral Therapy, outcomesModule primaryOutcomes measure: Client Satisfaction Questionnaire, primaryOutcomes measure: Internet Evaluation and Utility Questionnaire, primaryOutcomes measure: Internet Impact and Effectiveness Questionnaire, primaryOutcomes measure: Narrative Evaluation of Intervention Interview, primaryOutcomes measure: Recruitment Rate, primaryOutcomes measure: Completion of intervention, secondaryOutcomes measure: Beck Scale for Suicide Ideation, secondaryOutcomes measure: Patient Health Questionnaire-9, secondaryOutcomes measure: Posttraumatic Stress Disorder Checklist-5, secondaryOutcomes measure: Generalized Anxiety Disorder-7, secondaryOutcomes measure: Computerized Adaptive Testing - Suicide Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Eastern Colorado Health Care System, status: RECRUITING, city: Aurora, state: Colorado, zip: 80045, country: United States, contacts name: Lisa A Brenner, PhD, role: CONTACT, phone: 720-723-6488, email: Lisa.Brenner@va.gov, contacts name: Kelly A Stearns-Yoder, MA, role: CONTACT, phone: 720-723-6477, email: Kelly.Stearns@va.gov, geoPoint lat: 39.72943, lon: -104.83192, hasResults: False
protocolSection identificationModule nctId: NCT06375070, orgStudyIdInfo id: RMeng1, briefTitle: Anticoagulants for PFO Patients, statusModule overallStatus: COMPLETED, startDateStruct date: 2016-08, primaryCompletionDateStruct date: 2022-08, completionDateStruct date: 2022-08, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Xuanwu Hospital, Beijing, class: OTHER, descriptionModule briefSummary: Patients who underwent both bubble transcranial Doppler (bubble-TCD) and transoesophageal echocardiography (TEE) at our institution were consecutively enrolled in this real-world case-control study from August 2016 through August 2023. The patients were categorized into three groups based on the degree of the shunt observed: mild (3-9 bubbles), moderate (10-30bubbles), and severe (more than 30 bubbles). In cases with mild-shunt (small-size) PFO, post-procedural anticoagulation or PFO closure was administered. Subsequent to the interventions, the follow-up encompassed the recording of migraine remission, recurrent neurological incidents, instances of major bleeding, and mortality., conditionsModule conditions: Patent Foramen Ovale, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 277, type: ACTUAL, armsInterventionsModule interventions name: PFO closure, interventions name: anticoagulant, outcomesModule primaryOutcomes measure: whether occur recurrent stroke or migraine relief, eligibilityModule sex: ALL, minimumAge: 16 Years, maximumAge: 65 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06375057, orgStudyIdInfo id: asiamkfv49wurfpylld2m6g7cr4kz6, briefTitle: Relationship Between Acute Phase Markers and Post-operative Pain in Laparoscopic Cholecystectomy: An Observational Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-03-03, primaryCompletionDateStruct date: 2024-02-26, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: University of Roma La Sapienza, class: OTHER, descriptionModule briefSummary: Many patients undergoing laparoscopic cholecystectomy are prone to developing acute and chronic post-operative pain.The aim of the study is to show a possible correlation between pain and acute phase proteins in order to:* predict the severity of pain;* select most suitable pain relief therapy for the patient., conditionsModule conditions: Post Operative Pain, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 54, type: ESTIMATED, armsInterventionsModule interventions name: laparoscopic cholecystectomy, outcomesModule primaryOutcomes measure: Relationship Between Post-operative Pain and C Reactive Protein (CRP) in Laparoscopic Cholecystectomy, primaryOutcomes measure: Relationship Between Post-operative Pain and D-dimer in Laparoscopic Cholecystectomy, primaryOutcomes measure: Relationship Between Post-operative Pain and Fibrinogen in Laparoscopic Cholecystectomy, primaryOutcomes measure: Relationship Between Post-operative Pain and white blood cell count in Laparoscopic Cholecystectomy, primaryOutcomes measure: Relationship Between Post-operative Pain and Neutrophil to Lymphocyte Ratio (NLR) in Laparoscopic Cholecystectomy, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Augusto Lauro, status: RECRUITING, city: Roma, zip: 000186, country: Italy, contacts name: Augusto Lauro, role: CONTACT, phone: +39 388 8663 879, email: augusto.lauro@uniroma1.it, geoPoint lat: 41.89193, lon: 12.51133, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2023-03-03, uploadDate: 2024-04-16T07:17, filename: Prot_SAP_000.pdf, size: 179155, hasResults: False
protocolSection identificationModule nctId: NCT06375044, orgStudyIdInfo id: SIM0500-101, briefTitle: Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-30, primaryCompletionDateStruct date: 2026-06-30, completionDateStruct date: 2028-12-30, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Jiangsu Simcere Pharmaceutical Co., Ltd., class: INDUSTRY, collaborators name: Shanghai Xianxiang Medical Technology Co., Ltd., descriptionModule briefSummary: This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial., conditionsModule conditions: Relapsed or Refractory Multiple Myeloma, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 130, type: ESTIMATED, armsInterventionsModule interventions name: SIM0500, outcomesModule primaryOutcomes measure: Dose-limiting toxicity (DLT), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, city: Tianjin, state: Tianjin, zip: 300000, country: China, contacts name: Yan Xu, role: CONTACT, email: xuyan1@ihcams.ac.cn, geoPoint lat: 39.14222, lon: 117.17667, hasResults: False
protocolSection identificationModule nctId: NCT06375031, orgStudyIdInfo id: HR011408-103, briefTitle: Comparison of HR011408 and NovoRapid® in Subjects With Diabetics, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-07-01, completionDateStruct date: 2024-07-15, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Jiangsu HengRui Medicine Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The objective of the study is to compare the pharmacokinetics and pharmacodynamics between HR011408 and NovoRapid® in Subjects with Diabetics., conditionsModule conditions: Diabetes, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: The study was designed as a multi-center, randomized, double-blind, three-cycle crossover, positive drug control (NovoRapid ®) To compare the pharmacokinetics, pharmacodynamics, safety, and tolerability of a single injection of HR011408 or NovoRapid ® before or after a standard meal test in patients with type 1 or type 2 diabetes., primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: HR011408 injection; HR011408 injection Placebo, interventions name: NovoRapid®; HR011408 injection Placebo, interventions name: HR011408 injection Placebo; HR011408 injection, outcomesModule primaryOutcomes measure: Area under the serum concentration-time curve of insulin aspart, secondaryOutcomes measure: Area under the serum concentration-time curve of insulin aspart, secondaryOutcomes measure: Plasma glucose concentration, secondaryOutcomes measure: Number of subjects with adverse events and severity of adverse events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 64 Years, stdAges: ADULT, contactsLocationsModule locations facility: The Second Hospital of Anhui Medical University, city: Hefei, state: Anhui, zip: 230601, country: China, contacts name: 230601 Pan, Doctor, role: CONTACT, phone: 0551-65997421, email: ptr1968@163.com, contacts name: Wei Hu, Doctor, role: CONTACT, phone: 0551-65997421, email: ayefygcp@163.com, geoPoint lat: 31.86389, lon: 117.28083, hasResults: False
protocolSection identificationModule nctId: NCT06375018, orgStudyIdInfo id: OST1_011, briefTitle: Effect of the Diaphragm Stretching Technique on Nonspecific Low Back Pain, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Escola Superior de Tecnologia da Saúde do Porto, class: OTHER, descriptionModule briefSummary: This study aims to analyze the efficacy of diaphragm stretching technique on symptomatology in young adults with nonspecific low back pain., conditionsModule conditions: Nonspecific Low Back Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Placebo Technique, interventions name: Diaphragm Stretching, outcomesModule primaryOutcomes measure: Change in level of inspiratory capacity immediately after intervention, primaryOutcomes measure: Change in the level of disability derived from low back pain immediately after the intervention, primaryOutcomes measure: Change in the level of functionality of the lumbar spine immediately after the intervention, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule locations facility: Escola Superior de Saúde do Porto, city: Porto, zip: 4200-072, country: Portugal, geoPoint lat: 41.14961, lon: -8.61099, hasResults: False
protocolSection identificationModule nctId: NCT06374992, orgStudyIdInfo id: Pro00114569, briefTitle: Family Involvement Hospital Ethnography, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-08, completionDateStruct date: 2024-08, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Duke University, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to learn about the role of family members in caring for hospitalized older adults with cognitive impairment. The main questions it aims to answer are:1. What features of the healthcare system facilitate or hinder family involvement in care from the perspective of patients, families, and healthcare workers?2. How do hospital leaders understand the facilitators and barriers to family involvement?Data collection will occur via semi-structure interviews, direct observation, and artifact analysis., conditionsModule conditions: Dementia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Faciltators and Barriers to Family Involvement in Care of Hospitalized Older Adults with Cognitive Impairment, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False